ABOUT OUR APPROACH OUR PRODUCTS INVESTORS CAREERS MEDICAL AFFAIRS CONTACT Our Products OVERVIEW Our Products Full US Prescribing Information Medication Guide Indications and Usage Link to xtampzaer.com IMPORTANT SAFETY INFORMATION See full Important Safety Information, including Boxed Warning on Addiction, Abuse and Misuse and other serious risks at XtampzaER.com/PI Full US Prescribing Information Medication Guide Indications and Usage Link to nucynta.com IMPORTANT SAFETY INFORMATION See full Important Safety Information, including Boxed Warning on Addiction, Abuse and Misuse and other serious risks at Nucynta.com/erPI Full US Prescribing Information Medication Guide Indications and Usage Link to nucynta.com IMPORTANT SAFETY INFORMATION See full Important Safety Information, including Boxed Warning on Addiction, Abuse and Misuse and other serious risks at Nucynta.com/irPI Xtampza® ER, NUCYNTA® ER and NUCYNTA® are registered trademarks of Collegium Pharmaceutical, Inc. © 2021 Collegium Pharmaceutical, Inc. info@collegiumpharma.com (781) 713-3699 PRIVACY POLICY TERMS OF USE SITE CREDITS © 2021

ABOUT OUR APPROACH OUR PRODUCTS INVESTORS CAREERS MEDICAL AFFAIRS CONTACT Contact CONTACT INFORMATION Contact Information Collegium Pharmaceutical, Inc. 100 Technology Center Drive, Suite 300 Stoughton, MA 02072 Email: info@collegiumpharma.com Phone: (781) 713-3699 info@collegiumpharma.com (781) 713-3699 PRIVACY POLICY TERMS OF USE SITE CREDITS © 2021

Skip to main navigation ABOUT OUR APPROACH OUR PRODUCTS INVESTORS CAREERS MEDICAL AFFAIRS CONTACT Investors OVERVIEW IR Navigation OVERVIEW PRESS RELEASES STOCK INFORMATION EVENTS & PRESENTATIONS CORPORATE GOVERNANCE SEC FILINGS CONTACT IR Overview Collegium Pharmaceutical is a specialty pharmaceutical company committed to being the leader in responsible pain management. For nearly two decades, Collegium has been focused on developing and commercializing new medicines for pain management that reflect our Core Values and our commitment to people suffering from pain, providers and our communities. The result of those efforts is a portfolio of meaningfully differentiated medications to treat moderate to severe pain. Press Releases November 15, 2021 Collegium Announces $25 Million Accelerated Share Repurchase Program November 11, 2021 Collegium to Participate in Upcoming Conferences November 4, 2021 Collegium Reports Third Quarter Fiscal 2021 Results VIEW ALL Upcoming Events Dec 1, 2021 Collegium Pharmaceutical, Inc. at the Piper Sandler 33rd Annual Healthcare Conference 2021 VIEW ALL NASDAQ: COLL $17.95 -0.58 (-3.13%) Data Provided by Refinitiv. Minimum 15 minutes delayed. Toolkit Print Page Email Alerts RSS Feeds info@collegiumpharma.com (781) 713-3699 PRIVACY POLICY TERMS OF USE SITE CREDITS © 2021